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a b s t r a c t
African horse sickness virus (AHSV) is an orbivirus, a member of the Reoviridae family. Nine different ser-
otypes have been described so far. AHSV is vectored by Culicoides spp. to equids, causing high mortality,
particularly in horses, with considerable economic impacts. For development of a safe attenuated vaccine,
we previously established an efficient reverse genetics (RG) system to generate Entry Competent
Replication-Abortive (ECRA) virus strains, for all nine serotypes and demonstrated the vaccine potential
of these strains in type I interferon receptor (IFNAR)-knockout mice. Here, we evaluated the protective
efficacies of these ECRA viruses in AHSV natural hosts. One monoserotype (ECRA.A4) vaccine and one
multivalent cocktail (ECRA.A1/4/6/8) vaccine were tested in ponies and subsequently challenged with
a virulent AHSV4. In contrast to control animals, all vaccinated ponies were protected and did not develop
severe clinical symptoms of AHS. Furthermore, the multivalent cocktail vaccinated ponies produced neu-
tralizing antibodies against all serotypes present in the cocktail, and a foal born during the trial was
healthy and had no viremia. These results validate the suitability of these ECRA strains as a new gener-
ation of vaccines for AHSV.
 2017 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).
1. Introduction
African horse sickness (AHS) is an infectious arthropod-borne
viral disease of equids, such as horses, donkeys, mules and zebras.
In naïve horses, AHS virus (AHSV), a member of orbivirus genus,
causes different forms of disease ranging from mild fever to an
acute form, characterized by high fever, respiratory distress,
lethargy and a mortality rate of over 90% [1]. AHSV is endemic in
sub-Saharan Africa, although in the past, periodic outbreaks of
AHSV have occurred in North African countries and southern Eur-
ope, such as Spain and Portugal [2]. Like closely related Orbiviruses
such as bluetongue virus (BTV) and epizootic haemorrhagic disease
virus (EHDV), AHSV is vectored by Culicoides midges, some species
of which are present in Europe and the United states. In view of the
recent emergence of BTV into Northern Europe, a region consid-
ered low risk for BTV introduction, the spread of AHSV outbreaks
in Northern countries is a possibility. In order to control the disease
in Africa, vaccination with a polyvalent live-attenuated vaccine
(LAV) is currently used but it is considered to be unsafe due to
the possibility of virulent revertants and the potential of reassort-
ment between LAV and wild-type AHSV strains [3,4].
AHSV is a non-enveloped virus containing a genome of 10
double-stranded RNA (dsRNA) segments (S1 to S10). Nine sero-
types of AHSV (AHSV1 to AHSV9) have been described, whereas
more than 27 BTV serotypes have been reported to date [5]. At
sequence level, these viruses are highly diverse, however, AHSV
is structurally closely related to BTV [6]. The double capsid viral
particle is composed of seven proteins organized in concentric lay-
ers: an outer capsid, comprised of two major structural proteins
VP2 and VP5 and an inner capsid, termed a core, consisting of a
surface layer, made of VP7 and an inner layer, made of VP3. The
inner layer encloses the replication complex consisting of three
proteins, VP1, VP4, and VP6 and the genome of 10 dsRNA segments
[7]. The design of safe AHSV vaccines, mainly based on the AHSV
neutralization protein, VP2 protein, have been developed using
various live vectors or as recombinant subunit vaccines but none
have yet been commercialized [8–10]. Furthermore, since VP2 is
serotype specific, AHSV vaccines for all nine serotypes are required
in order to achieve protections against infection by all AHSV
serotypes.
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Reverse genetics (RG) is one of the most powerful tools to
decipher viral replication processes and information gained by
its use could be utilized for the development of novel and
highly efficacious multivalent vaccines and a RG-based, live-
attenuated AHSV4 vaccine candidate has shown promising
results [11]. Our aim here was to produce replication-abortive
viruses, which could not replicate in the vaccinated host and
thus, significantly decrease the risk of viremia and potential
reassortments with wild-type viruses. Indeed, development of
such vaccine candidates were possible for BTV using a synthetic
RNA-based RG system [12]. We demonstrated that while these
vaccine strains were highly efficient to enter, but were unable
to replicate in normal cells as genomic dsRNA molecules are
not synthesised. These Entry Competent Replication Abortive
(ECRA) virus strains (formally known as DISC) are deficient in
VP6 (encoded by S9), and cannot complete even a single repli-
cation cycle. However, they still initiate the replication cycle
and synthesize a single round of viral mRNAs following entry
and express viral proteins in normal cells. Vaccine production
of such strains is achieved by growth in a helper cell line that
expresses VP6 in trans [13]. The protective abilities of such
BTV strains were assessed in BTV-susceptible sheep demonstrat-
ing that strong protection against virulent virus challenge was
afforded in the vaccinated animals. Subsequently, several vac-
cine trials in sheep and cattle were undertaken and the cumu-
lative data confirmed the stability, protective efficacy and
safety of these strains and their suitability as next generation
vaccines for BTV [13–15].
With the aim of developing highly efficient candidate vaccines
against all AHSV serotypes, particularly taking into account
immunogenicity, safety and virus productivity aspects, we first
established a highly efficient RG system for AHSV serotype 1,
AHSV1 [16]. Subsequently, replication-abortive AHSV strains
(ECRA.AHSV) of each of the nine serotypes were generated by
introducing multiple stop codons in the coding region of segment
S9, disrupting the ORF encoding VP6, an essential catalytic compo-
nent of genome replication as well as the overlapping ORF of the
NS4 protein [16]. Preliminary protective efficacy studies with these
VP6-deficient virus strains in AHSV-sensitive mice lacking the type
I interferon receptor (IFNAR), showed that vaccinated mice were
protected against homologous virulent virus challenge, demon-
strating the suitability of the ECRA-AHSV variants as a vaccine can-
didate. In this study, we sought to extend the vaccine protection
trials to ponies, the natural host of AHSV. Two different vaccine
regimes, a monoserotype (ECRA.A4) vaccine and a multivalent,
cocktail vaccine of 4 different AHSV serotypes (ECRA.A1/4/6/8)
were used in ponies followed by virulent virus challenge with
one serotype. Results from clinical and immunological analyses
demonstrated the protection efficacies of ECRA vaccines in ponies.
Further, our data suggest that a cocktail of RG-based ECRA-AHSV
strains may be suitable to be used as a multivalent vaccine in
equids.
2. Methods
2.1. Cell lines and viruses
BSR cells (BHK-21 subclone) were maintained in Dulbecco mod-
ified Eagle medium (DMEM, Sigma) supplemented with 5% foetal
bovine serum (FBS; Invitrogen). The stable cell line BSR-VP6 was
generated by electroporation of AHSV1-VP6 expressing vector
(pCAG-AHSV1 VP6), grown in DMEM supplemented with 5% FBS,
and with 7.5 mg/ml of puromycin (Sigma) and tested by
immunoblotting analysis [16,17].
2.2. Recovery of replication-abortive AHSV variants
VP6-deficient AHSV1 (ECRA.A1) was generated as previously
described [16]. Briefly, BSR cells stably expressing AHSV VP6 were
transfected with 5 pCAG plasmids carrying the genes of VP1, VP3,
VP4, VP6 and NS2, followed by transfection of 10 capped AHSV1
RNA transcripts: S1 to S8, S10, and S9multistop. To generate
ECRA.AHSV strains for other serotypes, several segments were used
to generate serotype-specific reassortants, by replacing equivalent
segments in parental AHSV1 as described [16]. Each deficient virus
was plaque-purified and titrated on BSR-VP6 cells.
For vaccination of ponies, the early passaged ECRA.AHSV stocks
(1–2 passages in BSR-VP6 cells) were amplified in BSR-VP6 cells at
an MOI 0.1 in antibiotic-free media and collected when complete
cytopathic effect (CPE) was observed (48–72 h post infection).
The resulting ECRA.AHSV stocks were supplemented with 10% tre-
halose (Sigma) and 1 ml aliquots were frozen in liquid nitrogen and
stored at 80 C until vaccination. The aliquots of frozen stocks
were titrated on BSR-VP6 cells and tested for the absence of repli-
cation in wild type BSR cells for at least 3 blind passages by visu-
alization of the absence of typical cytopathic effects and
confirmation by RT-PCR. The mock-vaccine doses were prepared
from an equivalent amount of BSR-VP6 cells via lysis by sonication.
2.3. Monoserotype and cocktail ECRA.AHSV vaccination in ponies
For vaccination, local breed ponies (poneys français de selle)
were purchased from a farmer in Normandy, France, most of which
were female and 2 geldings. Ponies were divided into two groups
of 4 animals, A and B groups. Ponies were between 1 and 3 years
old, except two (A4 and B4) that were older, over 10 years old.
The weight of ponies were also varied between 72 kg and 164 kg.
Ponies were subcutaneously inoculated with ECRA vaccine strains,
group A with ECRA.A4 virus (1  107 Plaque Forming Unit (PFU)/
animal) and group B with a cocktail of ECRA.A1/4/6/8
(1  107 PFU of each serotype/animal) at day 0. In addition, 2 ani-
mals were mock-vaccinated with uninfected cell lysates (Group C).
A booster injection was given 21 days after the first vaccination. At
day 36, two weeks after the booster vaccination, all animals were
challenged intravenously with 2  106 TCID50 of a virulent isolate
of AHSV4 (Morocco 1990) (kindly provided by José Manuel Sánch
ez-Vizcaíno, Universidad Complutense de Madrid, Spain). Chal-
lenge virus stock was obtained after 5 passages on Vero cells of a
spleen extract from an AHSV4 infected horse and subsequently
passaged in Culicoides cells (KC) once. Whole-blood and serum
samples of all animals were taken at regular intervals before and
after vaccination and challenge. This study was performed in strict
accordance with the French guidelines and recommendations on
animal experimentation and welfare. The protocol was approved
by the ANSES/ENVA/UPEC Animal Ethics Committee (Permit Num-
ber: 09/02/16-9, APAFiS 2016012115476384).
2.4. RNA extraction and RT-PCR
RNA was extracted from blood samples and from organs
(spleen, lung and heart) homogenized in 10%w/v PBS with the
QIAamp viral RNA kit and the Qiacube robot (QIAGEN). Genomic
double-stranded RNA extracts were heat treated prior to addition
to the RT-PCR reaction mix (addition of 10% DMSO and heating
at 95 C for 5 min). Real-time AHSV RT-PCR targeting the S1 seg-
ment was performed twice in three replicates according to estab-
lished method [18], with modifications necessitated for the RT-
PCR kit (AgPath-IDTM One-Step RT-PCR Kit (ThermoFisher Scientific)
instead of SuperScript III/Platinum Taq One-Step qRT-PCR Kit) and
to the cycling conditions in StepOne or AB7300 thermocycler:
45 C for 10 min, 95 C for 10 min followed by 45 cycles of 95 C
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for 10 s, 55 C for 30 s and 72 C for 30 s. Cycle threshold (Ct) values
were measured and values above a threshold of 40 were consid-
ered as negative.
2.5. Serology of monoserotype ECRA.A4 and cocktail ECRA.A1/4/6/8
trials
Serum samples were analysed by a commercially available
competitive ELISA AHSV VP7 Antibody Test kit (ELISA Ingezim
AHSV Compaq) according to manufacturer’s instructions. Serologi-
cal status was defined as positive (50%), doubtful (>45% and
<50%) or negative (45%). To detect neutralizing antibody
response, standard serum neutralization (SN) assay was used as
described previously [13] and titers were expressed as the recipro-
cal of the highest dilution of sera allowing complete neutralization
of 100 AHSV PFU.
2.6. Clinical monitoring
Ponies were monitored on a daily basis during 8 days after vac-
cination and 3 weeks after challenge for development of AHSV
clinical signs. General signs (behavioural modifications, hyperther-
mia, cardiac rate and breathing rhythm, sudation), as well as signs
of oedema, abnormal bleeding (petechiae), dyspnoea, nasal dis-
charge and conjunctivitis were recorded and scored according to
the following criteria:
Behaviour: Normal – 0pt, Apathy – 1pt, Depression – 2pt, Pros-
tration – 3pt
General parameters: rectal temperature (T) = Normal – 0pt,
39 C  T  40 C – 1pt, T > 40 C – 3pt; cardiac rate = Normal
– 0pt, >50 – 2pt; breathing rhythm = Normal – 0pt, >25 – 2pt
Specific signs: Oedema – 1pt per location (eyelids, supraorbital
fossa, lips, head, neck, trunk or disseminated), nasal discharge –
1pt per type of secretion (serous, mucous, purulent, haemor-
rhagic), petechial lesions – 1pt per location (conjunctivitis, oral
cavity, skin), dyspnoea – 1pt, cough – 1pt, conjunctivitis – 1pt,
abnormal sudation – 1pt, colic – 1pt.
3. Results
3.1. Preparation of ECRA vaccine strains of AHSV serotypes
By using the established BSR-VP6 complementary cell line,
ECRA.AHSV1 could be recovered by RG through transfection of 5
viral protein expression plasmids followed by transfection of 10
capped T7 RNA transcripts, where S9 was replaced by the S9multi-
stop segment disrupting the VP6 and NS4 ORFs [16]. After confirm-
ing that VP6 was efficiently complemented, we utilized the ECRA.
AHSV1 strain as a backbone to produce deficient strains for all
AHSV serotypes (2–9) by combining different segments. The
exchange of 2 segments (S2 + S6) allowed the recovery of ECRA.
A8 but 3 segments (S2 + S6 + S7) were required for the recovery
of ECRA.A4 and 4 segments (S2 + S6 + S7 + S3) for the recovery of
ECRA.A6 respectively (Fig. 1). Each vaccine strain was grown in
BSR-VP6 complementary cells, titred on the same cells and stored
in stabilised form [14] until the day of vaccination. For monosero-
type vaccination 1  107 PFU (ECRA.A4) were used per dose
whereas the cocktail vaccination (ECRA.A1/4/6/8) contained
1  107 PFU of each of the requisite ECRA-AHSV strains per dose.
The particular cocktail mix of vaccine strains was selected based
on the serological distances among these 4 serotypes.
3.2. ECRA vaccine strains do not replicate in ponies but trigger immune
responses
To assess the protective efficacy of the ECRA.AHSV strains
against AHSV4 infection in ponies, two groups (A & B) of 4 ponies
were immunized twice with the 1  107 PFU (ECRA.A4, group A) or
a total of 4  107 PFU for cocktail (ECRA.A1/4/6/8, group B). Unin-
fected, clarified cell lysates were inoculated to the control animals
(group C). Due to restrictions on available animal numbers (10
ponies), only one cocktail of four serotypes was tested in this
study. The primary vaccination was performed at day 0 (‘‘prime”),
and a repeated dose was inoculated for the booster vaccination at
day 21 (‘‘booster”).
Vaccinated ponies were routinely monitored from day 0 to day
35 but none showed any visible AHSV clinical reaction (Fig. 2A).
Similarly, the control non-vaccinated animals showed no reactions.
Thus, the ECRA.AHSV vaccine strains were well tolerated and
induced no adverse effect following immunization. Blood samples
were collected periodically to monitor viral load and antibody pro-
duction from day 0. Viral replication was monitored by RT-PCR of
the blood samples of the animals, as previously described [18].
As shown in Fig. 2B, from day 0 to day 35 viral RNA was either
not detectable at all or present at a very low level in the vaccinated
animals in both groups and were equivalent to the control animals.
The data indicated the absence of viral replication after two doses
of vaccination.
Development of an antibody response to the ECRA.AHSV strains
in ponies was initially monitored by a standard AHSV group speci-
fic VP7 antigen ELISA test. After the first vaccination, an immune
response in the animals was evident, which was enhanced after a
second vaccination (Fig. 3). All vaccinated animals of both groups
A and B were seroconverted and a high level (up to 80%) of anti-
bodies against VP7 could be detected at day 28 and day 35, i.e.,
at day 7 and 14 respectively after the second injection (Fig. 3).
The sera from the control, non-vaccinated animals (C1 & C2) had
no detectable VP7 antibody.
The immune response was further analysed by determining the
neutralization antibody titers in vaccinated versus control animals
(Table 1A). Serum samples collected at day 21 had very low, if any,
neutralizing antibody (NA) titer against any serotypes (data not
shown). However, sera collected at day 35 (two weeks after the
booster vaccination and prior to challenge) of ECRA.A4
monovalent-vaccinated animals had NA titers ranging from 8 to
64 against AHSV4 (Table 1A). All animals in group B, vaccinated
with the cocktail vaccine, had NAs against the 4 serotypes present
Fig. 1. Vaccine Strains preparation. Schematic representation of the ECRA.AHSV vaccine strains obtained by reassortment. Vaccine strains ECRA.AHSV 4, 6 and 8 were
obtained by reassortment of segments encoding the structural proteins (VP2, VP3, VP5, VP7) as indicated (modified from [1]).
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in the vaccine cocktail, although the titers to each serotype varied
(from 4 up to 64) from animal to animal (Table 1A), indicating that
ECRA vaccine strains triggered neutralizing antibody responses in
vaccinated animals.
3.3. Protection against virulent virus challenge in vaccinated animals
To determine the protective efficacy of the vaccine strains, two
weeks after the booster vaccination, control and vaccinated ani-
mals were challenged with 2  106 TCID50 of virulent AHSV4, the
most pathogenic virus of the serotypes used. To monitor virus load
and neutralizing antibody production, blood samples were col-
lected from each animal at regular intervals until 4 weeks after
the challenge. One pony of the cocktail vaccinated group, B4, was
found to be pregnant during the trial and was monitored for virus
replication until the birth of the foal.
High titers of neutralizing antibodies against AHSV4 were
detected at day 44 (8 days post challenge) in both group A and
group B animals and some sera had NA titers against AHSV4 as
high as 256 (Table 1B). The serum of pony A4, of group A, had an
increased level of neutralizing antibody titer against AHSV4 by
day 8 after challenge which increased to 256 at day 60 (24 days
after challenge) (Table 1B). Neutralizing antibody titers up to 32
were also detected 8 days after challenge against AHSV1, AHSV6
Fig. 2. Clinical signs and viral replication in vaccinated animals. Animals were vaccinated twice at Day 0 and Day 21 (boost). (A) Clinical signs were scored based on body
temperature, breathing rhythm, cardiac pulses, etc. Four animals were vaccinated with ECRA.A4 (group A; top panel), four with a cocktail of ECRA.A1/4/6/8 (group B; lower
panel) and two animals were used as control (C1 & C2). (B) AHSV genomic RNA in serum was determined by RT-PCR and expressed as Ct values. Virus load is represented by a
colour gradient from green (ND: not detected) to red (Ct less than 25). (For interpretation of the references to colour in this figure legend, the reader is referred to the web
version of this article.)
Fig. 3. Seroconversion of animals after vaccination. The immune response of the
vaccinated animals were monitored by VP7 group specific competitive ELISA.
Animals in group A (top panel) and group B (bottom panel) were vaccinated twice
with ECRA.A4 or ECRA.A1/4/6/8 respectively, 21 days apart and compared to group
C (mock vaccinated animals).
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and AHSV8 in certain ponies of group B. Twenty-four days after
challenge (day 60 after vaccination) neutralizing antibodies against
AHSV4 were generally higher after the challenge in all animals of
both groups, presumably due to the memory response triggered
by the challenge virus. The B group ponies that elicited neutralizing
antibodies against AHSV1, AHSV6 and AHSV8 after vaccination also
sustained neutralizing antibody titers up to 32 at day 60 (Table 1B),
indicating the immune response of the vaccine strains in natural
hosts, either when used individually or in a cocktail. No neutraliz-
ing antibodies were detectable in the two control animals (C1 and
C2) (Table 1B).
None of the vaccinated animals in either group A or group B
showed any significant clinical signs post challenge (Fig. 4A top
and middle panel respectively). One vaccinated animal, A2, showed
mild circulatory (oedema of the eyelids, nasal discharge and mod-
erate dyspnoea) and respiratory symptoms for two days only (6–
8 days’ post challenge) (Fig. 4A, top panel). This was probably
due to partial protection afforded by lower neutralizing antibody
level developed after vaccination (Table 1B). As expected both con-
trol animals started to show clinical signs shortly (6–7 days) after
virulent virus challenge, with apathy, high hyperthermia and respi-
ratory distress, oedema of the eyelids and supraorbital fossae as
well as nasal discharge. These animals were euthanized at 10 days
(C2) and 11 days (C1) post challenge respectively (Fig. 4B).
Necropsy performed on both control animals highlighted marked
pulmonary oedema and pericardial and pleural effusions, which
are consistent with AHSV infection.
Both animals of the control group showed high viral loads (Ct
values of 26.9 and 27.1), by RT-PCR, 4 days after challenge which
increased until 8 days after challenge (Ct of 17.5 and 15.6)
(Fig. 5), consistent with the severe clinical symptoms observed in
these ponies (Fig. 4A, bottom panel, and 4B). RT-PCR analysis of
post mortem animals detected the presence of AHSV4 RNA in the
hearts, spleens and livers of C1 and C2 ponies (Ct from 14.85 to
20.37, data not shown). In contrast, all vaccinated animals of group
A and group B showed very low levels of viral RNA from 2 to 8 days
after challenge with virulent virus strain (Ct from 31.4 to 37.2). For
certain animals e.g. A4 and B4, RT-PCR signals consistent with a
transient, low level viremia, were detected (Ct from 30.1 to 38.1,
Fig. 5), 12 days after the challenge. However, no CPE was observed
after 4 passages of the blood in Vero cells and no live virus was
ever recovered, suggesting de facto protection from viremia despite
the low RT-PCR signals (data not shown). During the course of the
study animal B4 was found to be pregnant, however, the foal born
subsequent to the challenge showed no viral RNA detected by RT-
PCR. The foal was born on day 59 after the first vaccination and
presumably after 345 days (±7 days) gestation period. It is note-
worthy that virulent virus challenge was performed on day 322
of gestation and the first and second vaccine doses were inoculated
on day 286 and day 307 respectively, of gestation. The new born
foal had AHSV maternal antibodies detected at day 60 post prime
vaccination and was completely healthy without any sign of AHS
disease. The data indicated that the challenged virulent virus did
not cross the placenta.
Taken altogether, these data demonstrate the safety of both
ECRA.A4 and ECRA.A1/4/6/8 vaccination and the clinical
protection afforded to vaccinated animals against a virulent
AHSV4.
Table 1A
Serum neutralization activity in ponies after vaccination. Neutralizing activity in sera was determined by SN assay at Day 35 (one day before challenge) against AHSV serotypes 1,
4, 5, 6 and 8 as indicated. Titers were expressed as the reciprocal of the highest dilution of sera allowing complete neutralization. Not determined (nd) and not detected (-) are
indicated.
Group Animal ID Neutralizing antibody titers
Day 35 of vaccination
AHSV 1 AHSV 4 AHSV 5 AHSV 6 AHSV 8
A
ECRA.A4
A1 nd 64 – nd nd
A2 nd 32 – nd nd
A3 nd 64 – nd nd
A4 nd 8 – nd nd
B
ECRA .A1/4/6/8
B1 16 16 – 8 8
B2 8 16 – 4 8
B3 16 64 – 32 16
B4 4 8 – 8 4
C
Control
C1 – – – – –
C2 – – – – –
Table 1B
Serum neutralization activity in ponies after virulent virus challenge. Neutralizing antibody titers of vaccinated animal sera were determined by SN assay at day 8 and day 24 (44
and 60 days post challenge) against serotypes AHSV 1, 4, 5, 6 and 8. Titers were expressed as the reciprocal of the highest dilution of sera allowing complete neutralization. Both
C1 and C2 ponies were euthanized respectively at 11 days and 10 days’ post challenge due to severe AHS symptoms. Not determined (nd) and not detected (–) are indicated.
Group Animal ID Neutralizing antibody titers
8 days after challenge 24 days after challenge
AHSV 1 AHSV 4 AHSV 5 AHSV 6 AHSV 8 AHSV 1 AHSV 4 AHSV 5 AHSV 6 AHSV 8
A
ECRA.A4
A1 nd 64 nd nd nd nd 32 nd nd nd
A2 nd 32 nd nd nd nd 16 nd nd nd
A3 nd 256 nd nd nd nd 64 nd nd nd
A4 nd 64 nd nd nd nd 256 nd nd nd
B
ECRA .A1/4/6/8
B1 16 32 – 4 8 8 16 – 4 8
B2 – 64 – – 8 4 32 – – 4
B3 4 256 4 16 32 4 128 – 16 32
B4 – 256 4 – 8 – 32 – – –
C
Control
C1 – 4 – – – nd nd nd nd nd
C2 – – – – – nd nd nd nd nd
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4. Discussion
Although RG systems for orbiviruses have been developed fairly
recently, they have revolutionized not only the basic understand-
ing of orbivirus replication but also the field of vaccine design. In
particular, several RG-based vaccines have been developed for
BTV and several of these candidate vaccines afforded protective
immunity when tested in BTV susceptible animals (reviewed in
[19]). However, RG-based AHSV vaccines have not yet been shown
to be protective in horses. Our study here is the first report of a
horse study of a RG-based AHSV vaccine and shows great potential
to control AHS disease. This is a significant finding in the context of
the live attenuated vaccines (LAVs) that are used in South Africa
routinely as recent reports suggest these LAV vaccines pose consid-
erable risks, due to their high reversion rates and reassortment of
their genome segments with circulating strains, as well as their
potential transmission by vectors [4]. In our current study we used
our recently developed ECRA vaccine strains to assess their
Fig. 4. Clinical protection in vaccinated ponies after virulent virus challenge. Clinical signs were monitored from day 36 onwards. (A) Clinical signs were scored for vaccinated
groups A and B (up to 18 days) and control group (up to 10 days) (upper, middle and lower panels, respectively). (B) Severe clinical signs after challenge in both control
animals were evident as oedema of the eyelids and supraorbital fossae (left) and conjunctivitis (right).
Fig. 5. Absence of virus replication in vaccinated animals. Viremia in blood samples was determined by RT-PCR. Ct values are represented with a colour gradient from green
(high) to red (low) corresponding low to high viral loads. Values above 40 were considered as not detected (ND). Control animals in group C (C1 & C2) were respectively
euthanized at 11 and 10 days post challenge, due to severe AHS symptoms (black). (For interpretation of the references to colour in this figure legend, the reader is referred to
the web version of this article.)
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protective efficacy in ponies [16]. Prior to vaccination, we estab-
lished that AHSV-ECRA strains behaved similarly to previously
reported BTV DISC (ECRA) vaccine strains, consistent with both
BTV and AHSV vaccines lacking segment S9, an essential viral gene
[13]. The ECRA.AHSV vaccines were incapable of replicating in any
cell line except a VP6-complementing cell line and they did not
revert to a full cycle replication-capable virus upon passage in tis-
sue culture [16]. However, in AHSV-susceptible normal cells, ECRA
AHSV strains enter as efficiently as the wild-type viruses and
release the transcriptionally active core into the cytoplasm. Subse-
quently ECRA core particles synthesize mRNA transcripts only
once, which in turn are translated to viral proteins, except VP6
(and NS4), since S9 is defective. But de novo negative strands and
genomic dsRNA molecules are not generated, furthermore no func-
tional core is assembled. Such replication abortive ECRA.AHSV par-
ticles were shown to afford complete protection against
homologous virus infection in type I interferon receptor (IFNAR)-
knockout mice [16].
In the current study, we found that vaccination of ponies with
ECRA strains induced no adverse effect, as anticipated, but that
all animals seroconverted, particularly after a second vaccination.
Importantly, all vaccine strains were shown to be incapable of
replicating in animals, as expected from the absence of the essen-
tial VP6 protein. Animals in group B, which were vaccinated with
the multivalent vaccine, had NAb titers against AHSV1, AHSV4,
AHSV6 and AHSV8, the four ECRA vaccine strains present in the
cocktail. These ECRA.AHSV strains used the ECRA.A1 backbone
with other exchanged segments, notably segment-2 expressing
the neutralization protein, VP2. The development of neutralizing
antibody responses against each serotype included in the multiva-
lent vaccine (ECRA.A1/4/6/8) suggested no significant interference
in the immune response to each vaccine strain, and thus indicate
that more complex multivalent vaccines may be possible [11].
The multivalent vaccine did not elicit NA production to heterol-
ogous AHSV serotypes, such as AHSV5, most likely due to phyloge-
netic distance of the target from the immunising cocktail [20].
Thus, our data suggests that vaccine strains of all serotypes may
be needed in the cocktails in order to provide protective neutraliz-
ing antibodies against all AHSV serotypes.
The absence of ECRA.AHSV replication in vaccinated ponies was
examined by RT-PCR with Ct values at either undetectable, or
detectable only at very low level (range of 35–40), which gradually
became undetectable. The detection of AHSV RNA at a low level, by
a S1 primer was most likely due to residual genomes from the vac-
cination and the dose inoculated was 1  107 particles, which cor-
responds to the 1  107 copies of each dsRNA genomic segment.
Such an amount of RNA can still be detected in vaccinated animals
for a short duration without any replication in contrast to the
rapidly increasing signal of genome replication observed in non-
vaccinated challenged animals.
The immune responses elicited by monovalent ECRA.A4 or mul-
tivalent ECRA.A1/4/6/8 were sufficient to confer protection against
virulent AHSV4 challenge in ponies, with the exception of one ani-
mal, A2, which developed transient low level clinical symptoms,
but subsequently recovered. Interestingly, no significant increase
of viral load in the bloodstream of this animal was detected. In
another animal of the same group, A4, viral RNA was detected tran-
siently after challenge; however, no disease was observed. In con-
trast to the vaccinated animals, the two control animals suffered
severe AHS clinical symptoms including hyperthermia, respiratory
distress, oedema of the eyelids and supraorbital fossae, pulmonary
oedema and pericardial as well as pleural effusions.
Animal B4 was discovered to be pregnant during the study but
nonetheless tolerated the multivalent ECRA.AHSV vaccine and gave
birth to a healthy foal 25 days after challenge. The foal was free of
any detectable virus and was seropositive for antibodies to AHSV,
presumably maternal antibodies. Transplacental transmission of
AHSV and related viruses has been described [21–23]. While tradi-
tional LAV for BTV and AHSV can block viremia and reduce
transplacental transmission [24–26], the vaccines themselves are
teratogenic. Although requiring confirmation with higher num-
bers, our study indicates that the replication-abortive vaccine
strains maybe safe in pregnant ponies and maternal antibodies
can be beneficially transferred to the foal.
It is important to note that the production of the ECRA.AHSV
vaccine can be undertaken at BSL-2 conditions, since no infectious
materials are involved at any stage. Such a process would dramat-
ically decrease cost in comparison to the killed vaccine, which
requires the generation of high titers of pathogens in high contain-
ment laboratories with subsequent inactivation and additional
quality control steps. The ECRA.AHSV vaccine titer was as high as
1  108 PFU/ml, and thus corresponds to 10 doses which were
harvested from a culture of 1  107 BSR-VP6 cells. Thus, such vac-
cines are not only cost efficient but likely to be manufactured
rapidly as required.
During the last two decades, many attempts have been made to
develop safe and efficacious AHSV vaccines. Such vaccines have the
potential to be modified further for DIVA (Differentiate Infected
from Vaccinated Animals) and could significantly reduce the possi-
bility of recombination or reassortment with field strains and vec-
tor transmission. ECRA.AHSV vaccines are present in the
vaccinated host only transiently as they fail to replicate yet provide
a sufficient immune response to enable protection. Such vaccines
have the safety profile of inactivated vaccines but the cost advan-
tage and innate immunity triggering properties of attenuated vac-
cines. Taken together, replication abortive vaccine strains are
excellent candidates for commercial development to control AHS.
5. Conclusion
We generated replication-abortive AHSV strains and assessed
their protective efficacy in ponies. Vaccinated animals were pro-
tected against virulent virus challenge demonstrating the suitabil-
ity of these deficient viruses as vaccines in animals. However,
further studies are needed to understand the mechanisms of pro-
tective immunity, its longevity and to determine the minimum
dose requirement in order to develop this vaccine platform for
rapid responses to an outbreak with single or multiple AHSV
serotypes.
Funding
This work was funded by Biotechnology and Biological Sciences
Research Council (BB/K015168/1).
Conflicts of interests
The authors declare that they have no conflicts of interests.
References
[1] Mellor PS, Hamblin C. African horse sickness. Vet Res 2004;35:445–66.
[2] Zientara S, Weyer CT, Lecollinet S. African horse sickness. Rev Sci Tech
2015;34:315–27.
[3] Oura CA, Ivens PA, Bachanek-Bankowska K, Bin-Tarif A, Jallow DB, Sailleau C,
et al. African horse sickness in The Gambia: circulation of a live-attenuated
vaccine-derived strain. Epidemiol Infect 2012;140:462–5.
[4] Weyer CT, Grewar JD, Burger P, Rossouw E, Lourens C, Joone C, et al. African
horse sickness caused by genome reassortment and reversion to virulence of
live, attenuated vaccine viruses, South Africa, 2004–2014. Emerg Infect Dis
2016;22:2087–96.
[5] Zientara S, Sailleau C, Viarouge C, Hoper D, Beer M, Jenckel M, et al. Novel
bluetongue virus in goats, Corsica, France, 2014. Emerg Infect Dis
2014;20:2123–5.
4268 V. Lulla et al. / Vaccine 35 (2017) 4262–4269
[6] Manole V, Laurinmaki P, VanWyngaardt W, Potgieter CA, Wright IM, Venter GJ,
et al. Structural insight into African horsesickness virus infection. J Virol
2012;86:7858–66.
[7] Roy P. Orbiviruses and their replication. In: Knipe DM, Howley PM, editors.
Fields’ virology, fifth ed. Philadelphia, New York, USA: Lippincott Williams &
Wilkins; 2007. p. 1975–97.
[8] Alberca B, Bachanek-Bankowska K, Cabana M, Calvo-Pinilla E, Viaplana E, Frost
L, et al. Vaccination of horses with a recombinant modified vaccinia Ankara
virus (MVA) expressing African horse sickness (AHS) virus major capsid
protein VP2 provides complete clinical protection against challenge. Vaccine
2014;32:3670–4.
[9] Roy P, Bishop DH, Howard S, Aitchison H, Erasmus B. Recombinant
baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid
protein VP2 provides protection against virulent AHSV challenge. J Gen Virol
1996;77:2053–7.
[10] Scanlen M, Paweska JT, Verschoor JA, van Dijk AA. The protective efficacy of a
recombinant VP2-based African horsesickness subunit vaccine candidate is
determined by adjuvant. Vaccine 2002;20:1079–88.
[11] van de Water SG, van Gennip RG, Potgieter CA, Wright IM, van Rijn PA. VP2
Exchange and NS3/NS3a deletion in African Horse Sickness Virus (AHSV) in
development of disabled infectious single animal vaccine candidates for AHSV.
J Virol 2015;89:8764–72.
[12] Boyce M, Celma CC, Roy P. Development of reverse genetics systems for
bluetongue virus: recovery of infectious virus from synthetic RNA transcripts. J
Virol 2008;82:8339–48.
[13] Matsuo E, Celma CC, Boyce M, Viarouge C, Sailleau C, Dubois E, et al.
Generation of replication-defective virus-based vaccines that confer full
protection in sheep against virulent bluetongue virus challenge. J Virol
2011;85:10213–21.
[14] Celma CC, Stewart M, Wernike K, Eschbaumer M, Gonzalez-Molleda L, Breard
E, et al. Replication-deficient particles: new insights into the next generation
of bluetongue virus vaccines. J Virol 2017;91.
[15] Celma CC, Boyce M, van Rijn PA, Eschbaumer M, Wernike K, Hoffmann B, et al.
Rapid generation of replication-deficient monovalent and multivalent vaccines
for bluetongue virus: protection against virulent virus challenge in cattle and
sheep. J Virol 2013;87:9856–64.
[16] Lulla V, Lulla A, Wernike K, Aebischer A, Beer M, Roy P. Assembly of
replication-incompetent African horse sickness virus particles: rational design
of vaccines for all serotypes. J Virol 2016;90:7405–14.
[17] Matsuo E, Roy P. Bluetongue virus VP6 acts early in the replication cycle and
can form the basis of chimeric virus formation. J Virol 2009;83:8842–8.
[18] Bachanek-Bankowska K, Maan S, Castillo-Olivares J, Manning NM, Maan NS,
Potgieter AC, et al. Real time RT-PCR assays for detection and typing of African
horse sickness virus. PLoS One 2014;9:e93758.
[19] Dudek T, Knipe DM. Replication-defective viruses as vaccines and vaccine
vectors. Virology 2006;344:230–9.
[20] Kanai Y, van Rijn PA, Maris-Veldhuis M, Kaname Y, Athmaram TN, Roy P.
Immunogenicity of recombinant VP2 proteins of all nine serotypes of African
horse sickness virus. Vaccine 2014;32:4932–7.
[21] van der Sluijs M, Timmermans M, Moulin V, Noordegraaf CV, Vrijenhoek M,
Debyser I, et al. Transplacental transmission of Bluetongue virus serotype 8 in
ewes in early and mid gestation. Vet Microbiol 2011;149:113–25.
[22] Martinelle L, Dal Pozzo F, Sarradin P, De Leeuw I, De Clercq K, Thys C, et al.
Pulmonary artery haemorrhage in newborn calves following bluetongue virus
serotype 8 experimental infections of pregnant heifers. Vet Microbiol
2013;167:250–9.
[23] Crafford JE, Lourens CW, Gardner IA, Maclachlan NJ, Guthrie AJ. Passive
transfer and rate of decay of maternal antibody against African horse sickness
virus in South African Thoroughbred foals. Equine Vet J 2013;45:604–7.
[24] van der Sluijs MTW, Schroer-Joosten DPH, Fid-Fourkour A, Vrijenhoek MP,
Debyser I, Gregg DA, et al. Effect of vaccination with an inactivated vaccine on
transplacental transmission of BTV-8 in mid term pregnant ewes and heifers.
Vaccine 2012;30:647–55.
[25] van der Sluijs MTW, Schroer-Joosten DPH, Fid-Fourkour A, Smit M, Vrijenhoek
MP, Moulin V, et al. Transplacental transmission of BTV-8 in sheep: BTV
viraemia, antibody responses and vaccine efficacy in lambs infected in utero.
Vaccine 2013;31:3726–31.
[26] Monaco F, Bonfini B, Zaghini M, Antonucci D, Pini A, Savini G. Vaccination of
cattle using monovalent modified-live vaccine against bluetongue virus
serotype 2: innocuity, immunogenicity and effect on pregnancy. Vet Ital
2004;40:671–5.
V. Lulla et al. / Vaccine 35 (2017) 4262–4269 4269
